Potential cost savings to payers.

“Savings are due to increased use of active surveillance in low− and intermediate−risk patients, but also from reduced progression rates in high−risk patients with more aggressive disease who transition to multi−modality therapy.”

Crawford ED, Cole D, Lewine N, et al. Evaluation of the economic impact of the CCP assay in localized prostate cancer. Scientific poster presented at AUA-SCS 2015, ASCO-GU 2015, SUO 2014.

Learn More Download Poster